Literature DB >> 29030928

Pharmacokinetics of S-ketamine during prolonged sedation at the pediatric intensive care unit.

Robert B Flint1, Carole N M Brouwer2, Anne S C Kränzlin2,3, Loraine Lie-A-Huen1, Albert P Bos2, Ron A A Mathôt1.   

Abstract

BACKGROUND: S-ketamine is the S(+)-enantiomer of the racemic mixture ketamine, an anesthetic drug providing both sedation and analgesia. In clinical practice, significant interpatient variability in drug effect of S-ketamine is observed during long-term sedation. AIMS: The aim of this study was to evaluate the pharmacokinetic variability of S-ketamine in children aged 0-18 years during long-term sedation. Twenty-five children (median age: 0.42 years, range: 0.02-12.5) received continuous intravenous administrations of 0.3-3.6 mg/kg/h S-ketamine for sedation during mechanical ventilation. Infusion rates were adjusted to the desired level of sedation and analgesia based on the COMFORT-B score and Visual Analog Scale. Blood samples were drawn once daily at random time-points, and at 1 and 4 hours after discontinuation of S-ketamine infusion. Time profiles of plasma concentrations of S-ketamine and active metabolite S-norketamine were analyzed using nonlinear mixed-effects modeling software. Clearance and volume of distribution were allometrically scaled using the ¾ power model.
RESULTS: A total of 86 blood samples were collected. A 2-compartment and 1-compartment model adequately described the PK of S-ketamine and S-norketamine, respectively. The typical parameter estimates for clearance and central and peripheral volumes of distribution were: CLS-KETAMINE =112 L/h/70 kg, V1S-KETAMINE =7.7 L/70 kg, V2S-KETAMINE =545L/70 kg, QS-kETAMINE =196 L/h/70 kg, and CLS-NORKETAMINE =53 L/h/70 kg. Interpatient variability of CLS-KETAMINE and CLS-NORKETAMINE was considerable with values of 40% and 104%, respectively, leading to marked variability in steady-state plasma concentrations.
CONCLUSION: Substantial interpatient variability in pharmacokinetics in children complicates the development of adequate dosage regimen for continuous sedation.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  S-ketamine; S-norketamine; children; long-term; pharmacokinetics; sedation

Mesh:

Substances:

Year:  2017        PMID: 29030928     DOI: 10.1111/pan.13239

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  2 in total

1.  Extended Duration Ketamine Infusions in Critically Ill Children: A Case Report and Review of the Literature.

Authors:  Eszter Moore; Rebecca Mayes; Maura Harkin; Jamie L Miller; Peter N Johnson
Journal:  J Pediatr Intensive Care       Date:  2020-06-10

2.  Long-lasting neurocognitive disorders: a case report of previously undescribed adverse effects after ketamine sedation and analgesia in a pediatric patient.

Authors:  Kissila M Machado-Ferraro; Débora S Soriano-de-Mello; Isadora P de Moura; Cinthia C S M da Silveira; Emmerson C F de Farias; Mary L F Maia; Susan C D de Sales; Ana Emilia V Carvalho; Ismaelino M N Magno; Enéas A Fontes-Júnior; Cristiane S F Maia
Journal:  Ann Transl Med       Date:  2022-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.